Prostate Screening vs Control: Prostate Cancer Incidence

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.111	0.108	0.114	wilson	ClinicalTrials.gov
Risk in group 2	0.0995	0.0965	0.103	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	0.0114	0.00702	0.0157	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	1.11	1.07	1.16	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	1.13	1.08	1.18	log	ClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Prostate Screening than on Control	88	63.7	143	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: control.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Prostate Screening	Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.	4,250	38,340	OG001	ClinicalTrials.gov
Group 2	Control	Participants receive standard medical care.	3,815	38,345	OG000	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Prostate Cancer Incidence	ClinicalTrials.gov
Description	Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.	ClinicalTrials.gov
Time frame	Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.	ClinicalTrials.gov
Population	All male participants randomized were analyzed. An intention-to-treat analysis was performed.	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)	ClinicalTrials.gov
NCT number	NCT00002540	ClinicalTrials.gov
Phases	NA	ClinicalTrials.gov
Conditions	Prostate Carcinoma	ClinicalTrials.gov
Interventions	Laboratory Biomarker Analysis, Medical Examination Assessment, Screening Questionnaire Administration	ClinicalTrials.gov
Lead sponsor	National Cancer Institute (NCI)	ClinicalTrials.gov
Results first posted	2014-06-26	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT00002540?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.